Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
GCA
•
Large vessel vasculitis
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Is there benefit of addition of a DMARD such as methotrexate? Would you revisit diagnosis?
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
How would you treat a young patient who presents with coronary vasculitis and aortitis with persistently positive MPO but no other features of AAV?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
Do you utilize temporal artery ultrasound in your practice?
How do you approach tapering immunosuppression in a patient with a history of Susac Syndrome who has stabilized on MMF and IVIG?
How do you approach the management of aortitis in patients with ANCA-associated vasculitis?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
What features on CTA/MRA are most helpful for differentiating large vessel vasculitis from atherosclerosis?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?